Showing 3751-3760 of 6950 results for "".
- Alma Launches the Alma Hybrid and Alma TED Systems in Canadahttps://practicaldermatology.com/news/alma-launches-the-alma-hybrid-and-alma-ted-systems-in-canada/2461298/Alma Hybrid and Alma TED systems are now commercially available in Canada, the company reports. Alma Hybrid, the first laser platform to include an ablative 10,600 nm (CO2) laser and a non-ablative 1570 nm laser for skin resurfacing that offers a comprehensive solution to utilize each b
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- Tarek El Hoss Named Sr. Vice President of Market Development and Sales at MedXhttps://practicaldermatology.com/news/tarek-el-hoss-named-sr-vice-president-of-market-development-and-sales-at-medx/2461287/Tarek El Hoss is MedX Health Corp.’s New Senior Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and g
- FDA Clears Use of Apyx Medical’s Renuvion Handpiece for Improvement in Appearance of Lax Skinhttps://practicaldermatology.com/news/fda-clears-use-of-apyx-medicals-renuvion-to-improve-appearance-of-lax-skin/2461273/The U.S. Food and Drug Administration received 510(k) clearance for the use of Apyx Medical’s Renuvion APR Handpiece for certain skin contraction procedures. Specifically, the Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aest
- Survey: Chronic Hive Patients Unsatisfied with Quality of Life, Carehttps://practicaldermatology.com/news/survey-chronic-hive-patients-unsatisfied-with-quality-of-life/2461271/Only one-fourth of patients with chronic hives are satisfied with their current quality of life, according to a recent survey conducted by
- Health Canada Clears Cutera’s AviClearhttps://practicaldermatology.com/news/health-canada-clears-cuteras-aviclear/2461268/Health Canada has cleared Cutera, Inc.’s AviClear for the treatment of mild, moderate, and severe acne. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, in March 2022. In addition
- Sun Safety Day at Wrigley a Success for Sun Heroeshttps://practicaldermatology.com/news/sun-safety-day-at-wrigley-a-success-for-sun-heroes/2461261/As an extension of the Sun Heroes initiative, CeraVe's Sun Safety Day at Wrigley Field in partnership with Amy Brodsky, MD brought sun protection education to attendees as the Chicago Cubs hosted the Atlanta Braves. Dr. Brodsky founded
- Cynosure's New Tempsure eyeEnvi Handpiece Offers Improved Function and Greater Comforthttps://practicaldermatology.com/news/cynosures-new-tempsure-eyeenvi-handpiece-offers-improved-function-and-greater-comfort/2461258/Cynosure has added a new Tempsure eyeEnvi handpiece to its portfolio. Featuring innovative ergonomic pencil grip design and lighter piston tension required to activate the treatment, the company says the new handpiece is more comfortable for patients and providers, heating thinner tissue mor
- SCUBE3 May Stimulate Hair Growthhttps://practicaldermatology.com/news/scube3-may-stimulate-hair-growth/2461254/University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, according to a study published in
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri